Instituto de Investigación Biomédica de A Coruña (INIBIC)
Centro de investigación
Fondazione IRCCS Istituto Nazionale dei Tumori
Milán, ItaliaPublicaciones en colaboración con investigadores/as de Fondazione IRCCS Istituto Nazionale dei Tumori (13)
2024
-
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer
Clinical Lung Cancer, Vol. 25, Núm. 3, pp. 233-243.e8
-
Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Advances in Therapy
-
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
Journal of Extracellular Vesicles, Vol. 13, Núm. 2
2023
-
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry
JTO Clinical and Research Reports, Vol. 4, Núm. 1
2022
-
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations
European Journal of Cancer, Vol. 167, pp. 142-148
-
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations
European Journal of Cancer
2021
-
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
The Lancet Oncology, Vol. 22, Núm. 6, pp. 858-871
-
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 1, pp. 51-65
2019
2016
2015
-
Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey
Clinical Microbiology and Infection, Vol. 21, Núm. 6, pp. 604.e1-604.e9